Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial
Presented by Sherko Kuemmel, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium The WSG ADAPT trial in patients with HR-positive, HER2-negative breast cancer established that the combination of clinical risk, genomic risk, and endocrine response (Ki67 downregulation) allows optimal patient selection for endocrine therapy or chemotherapy in HR+/ HER2-negative early breast cancer. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Speaker 1: The
